Patents by Inventor Jason Grant Kettle

Jason Grant Kettle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961228
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: March 30, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Karl Magnus Nilsson, Annika Birgitta Margareta Astrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepisto, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
  • Publication number: 20210087196
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Ring A, Ring B and Ring C have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating MCT4 mediated diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 25, 2021
    Inventors: Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING, Gillian McGregor LAMONT, David BUTTAR, Jason Grant KETTLE
  • Publication number: 20210078981
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 28, 2020
    Publication date: March 18, 2021
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta ASTRAND, Neil Patrick GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Publication number: 20200223828
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation, pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Application
    Filed: April 26, 2018
    Publication date: July 16, 2020
    Inventors: Tudor GRECU, Jason Grant KETTLE, Martin John PACKER, Stuart Eric PEARSON, James Michael SMITH
  • Patent number: 10654835
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 19, 2020
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20200109153
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 9, 2020
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
  • Patent number: 10597405
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 24, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
  • Patent number: 10519152
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 31, 2019
    Assignee: AstraZeneca AB
    Inventors: Bin Yang, Jason Grant Kettle, Thomas George Christopher Hayhow, Timothy Gordon Rasmusson, Johannes Wilhelmus Maria Nissink, Charlene Fallan, Gillian McGregor Lamont
  • Publication number: 20190367490
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Application
    Filed: January 16, 2018
    Publication date: December 5, 2019
    Applicant: AstraZeneca AB
    Inventors: Karl Magnus NILSSON, Annika Birgitta Margareta ASTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTO, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
  • Publication number: 20190194190
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 27, 2019
    Inventors: Bin YANG, Jason Grant KETTLE, Thomas George Christopher HAYHOW, Timothy Gordon RASMUSSON, Johannes Wilhelmus Maria NISSINK, Charlene FALLAN, Gillian McGregor Lamont
  • Publication number: 20190177338
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 13, 2019
    Inventors: Jason Grant Kettle, Sharanjeet Bagal, Graeme Richard Robb, James Michael Smith, Frederick Woolf Goldberg, Doyle Joseph Cassar, James Lyman Feron
  • Publication number: 20190092760
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 10167276
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 1, 2019
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Astrand, Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20170320857
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 9, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 9714236
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 25, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
  • Publication number: 20170088543
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, Dedong WU, Wenzhan YANG, Tudor GRECU, James MCCABE
  • Patent number: 8399667
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: March 19, 2013
    Assignee: Astrazeneca AB
    Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
  • Publication number: 20130005727
    Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 10, 2012
    Publication date: January 3, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Robert Hugh BRADBURY, Laurent Francois Andre HENNEQUIN, Jason Grant KETTLE
  • Patent number: 7947676
    Abstract: The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: May 24, 2011
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • Publication number: 20110046108
    Abstract: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
    Type: Application
    Filed: January 25, 2007
    Publication date: February 24, 2011
    Applicant: AstraZeneca AB
    Inventors: Jason Grant Kettle, Jon Read, Andrew Leach, Bernard Christophe Barlaam, Richard Ducray, Christine Marie Paul Lambert-Van Der Brempt